NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

Published Date: 10 Jul 2023

A highly selective noncovalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor called pirtobrutinib has demonstrated promise in a recent clinical trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Having a tattoo could increase your risk of developing lymphoma.

2.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

3.

Exercise may help breast cancer survivors manage weight

4.

Research team uncovers the underpinnings of head and neck cancers

5.

Financial hardship common in patients with cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot